Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.63 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.63 |
| ▸ | HPGD | P15428 | 1/20 | 0.63 |
| ▸ | GAA | P10253 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.48 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 2/20 | 0.48 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.46 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19930457 | 0.87 | HSD17B10 (0.62) | HSD17B10KDM4EALDH1A1HPGDGAA | |
| SCHEMBL19930448 | 0.83 | SLC6A7 (0.55) | KDM4EALDH1A1SMN1; SMN2 | |
| SCHEMBL19930458 | 0.82 | SLC6A7 (0.54) | HSD17B10KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL18126733 | 0.82 | ADRB2 (0.59) | HSD17B10KDM4EALDH1A1HPGDGAA | |
| SCHEMBL19930455 | 0.81 | KDM4E (0.65) | HSD17B10KDM4EALDH1A1HPGDKMT2A | |
| SCHEMBL19930445 | 0.81 | ALDH1A1 (0.65) | KDM4EALDH1A1HPGDSMN1; SMN2THRB | |
| SCHEMBL19930449 | 0.78 | DPP4 (0.49) | HSD17B10ALDH1A1HPGDGAAKMT2A | |
| SCHEMBL19930459 | 0.74 | CA12 (0.54) | CA12CA1CA2CA7CA9 | |
| SCHEMBL19930462 | 0.74 | ALDH1A1 (0.64) | HSD17B10KDM4EALDH1A1GAAKMT2A | |
| SCHEMBL10723816 | 0.74 | RAB9A (0.80) | HSD17B10KDM4EALDH1A1HPGDGAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | 2018-03-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180064711-A1 | METHODS FOR TREATING CRYPTOSPORIDIOSIS USING TRIAZOLOPYRIDAZINES | CLPP, SI, SAMHD1 | HSD17B10 4133/4885KDM4E 3816/4885ALDH1A1 1257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.